Iridium/Brønsted acid cooperative catalyzed asymmetric allylicsubstitution reactions at the C5 position of indolines have been reported for the first time. The highly efficient protocol allows rapid access to various C5-allylated products in good to high yields (48–97%) and enantioselectivities (82% to >99% ee) with wide functional group tolerance. The transformations allow not only the formation
convenient and facile method was developed for the synthesis of 1,2,3-trisubstituted indolines. Starting from indolederivatives and ketones/aldehydes, the corresponding indoline products could be obtained with high yield by the hexamethylphosphoramide (HMPA) catalyzed indole Friedel–Crafts reaction, reduction and direct reductive amination process.
One‐Pot Transfer Hydrogenation Reductive Amination of Aldehydes and Ketones by Iridium Complexes “on Water”
作者:Lu Ouyang、Yanping Xia、Jianhua Liao、Renshi Luo
DOI:10.1002/ejoc.202001097
日期:2020.10.31
An efficient and practical one-pot transfer hydrogenation reductive amination of aldehydes and ketones with amines has been developed by using iridium complexes as catalysts and formic acid as hydrogen source in aqueous, providing an environmentalfriendly methodology for the construction of a wide range of functionalized amine compounds in excellent yields (80%~95%) This effective methodology can
<i>cine</i>-Silylative Ring-Opening of α-Methyl Azacycles Enabled by the Silylium-Induced C–N Bond Cleavage
作者:Jianbo Zhang、Sukbok Chang
DOI:10.1021/jacs.0c05241
日期:2020.7.22
exo-dehydrogenation of alicyclic amine, (ii) hydrosilylation of resultant enamine, (iii) silylium-induced cis-β-amino elimination to open the ring skeleton, and (iv) hydrosilylation of terminal olefin. The present borane catalysis also works efficiently for the C-Nbondcleavage of acyclic tertiary amines. On the basis of experimental and computational studies, the silicon atom was elucidated to play a pivotal
Indolyl derivatives as liver-X-receptor (LXR) modulators
申请人:Dehmlow Henrietta
公开号:US20050245515A1
公开(公告)日:2005-11-03
The invention relates to compounds of formula (I):
and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, A, m, n and p are defined as in claim
1.
These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.